Delving into the Latest Updates on SPH Biotherapeutics (Shanghai) Limited with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Autologous CAR-T

Antibody

CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Immune System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Autologous CAR-T	1
Antibody	1
CAR-T	1

Top 5 Target	Count

PDL1 x ROR1	1
CD19 x CD22	1
ROR1(Inactive tyrosine-protein kinase transmembrane receptor ROR1)	1

主要目的：评价B019 注射液在受试者中的安全性和耐受性，确认B019 注射液在受试者中的最大耐受剂量（ MTD）或II 期研究推荐剂量（ RP2D）；。次要目的：评价B019注射液在受试者中的初步临床疗效；评价B019注射液输注后在受试者体内的药代动力学（PK）及药效学（PD）特征；评价B019注射液输注后在受试者中的免疫原性；评价B019 注射液输注在受试者中输注的可行性。

[Translation]

Primary purpose: To evaluate the safety and tolerability of B019 injection in subjects, and to confirm the maximum tolerated dose (MTD) or recommended dose (RP2D) of B019 injection in subjects. Secondary purpose: To evaluate the preliminary clinical efficacy of B019 injection in subjects; to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of B019 injection in subjects after infusion; to evaluate the immunogenicity of B019 injection in subjects after infusion; to evaluate the feasibility of infusion of B019 injection in subjects.

Start Date11 Sep 2024

Sponsor / Collaborator

SPH Biotherapeutics (Shanghai) Limited

100 Clinical Results associated with SPH Biotherapeutics (Shanghai) Limited

Login to view more data

0 Patents (Medical) associated with SPH Biotherapeutics (Shanghai) Limited

Login to view more data

100 Deals associated with SPH Biotherapeutics (Shanghai) Limited

Login to view more data

100 Translational Medicine associated with SPH Biotherapeutics (Shanghai) Limited

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Phase 1 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

B-019 ( CD19 x CD22 )	Pre B-cell acute lymphoblastic leukemia More	Phase 1
PD1/SNIPR-Based ROR1 CAR-T Cells(SPH Biotherapeutics) ( PDL1 x ROR1 )	Neoplasms More	Preclinical
Target ROR1 Antibody(SPH BIOTHERAPEUTICS SHANGHAI) ( ROR1 )	Neoplasms More	Discovery